Shanghai Vinnerna Biosciences Co., Ltd.
10
0
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
20.0%
2 terminated/withdrawn out of 10 trials
75.0%
-11.5% vs industry average
20%
2 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Effect of Pharmacokinetics in Healthy Chinese Subjects
Role: lead
The Mass Balance Study of [14C]JT001
Role: lead
A Real-World Study of JT001 for COVID-19
Role: lead
A Study in Elderly Chinese Subjects With Underlying Diseases
Role: lead
A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function
Role: lead
A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Role: lead
JT001 (VV116) for the Treatment of COVID-19
Role: lead
Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets
Role: lead
Efficacy and Safety of JT001 (VV116) Compared With Favipiravir
Role: lead
A Real-world Retrospective Study of Disease Outcomes in Non-severe COVID-19 Patient
Role: lead
All 10 trials loaded